Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR AVANIR Pharmaceuticals, Inc. Over the course of the 12-week research in the MS individual subset, Zenvia 30/10 mg fulfilled the primary efficacy endpoint by reducing PBA show prices by an incremental 11.9 percent beyond placebo Read more about this drug . These data provide extra insight into the clinical utility of Zenvia and help form our plans for long term drug development. All MS sufferers enrolled in the analysis assessed their daily pain regardless of baseline discomfort level or usage of concomitant analgesics. Mean pain scores in MS patients were decreased from baseline across time in the Zenvia 30/10 mg group.
About PLATO PLATO was a big , head-to-head patient outcomes research of ticagrelor versus clopidogrel, both given in combination with aspirin and various other standard therapy, made to establish whether ticagrelor could accomplish a clinically meaningful reduction in CV end factors in ACS patients, far beyond those afforded by clopidogrel. The study demonstrated that treatment with BRILINTA resulted in a greater reduction in the primary end point – a composite of CV death, MI, or stroke – compared to individuals who received clopidogrel [9.8 percent vs. 11.7 percent at 12 months, 1.9 percent absolute risk decrease , 16 percent relative risk reduction , 95 percent CI, 0.77 to 0.92, p.. Extra Analyses from PLATO Presented at ESC Congress AstraZeneca today announced results from a blinded overview of clinical data from sufferers in the PLATO trial who had died following coronary artery bypass graft surgery.